Laura D. Locati
University of Milan
CancerSurgeryPathologyOncologyHead and neck cancerInduction chemotherapyChemotherapyHead and neck squamous-cell carcinomaCarcinomaSalivary gland cancerSalivary glandAdenoid cystic carcinomaThyroid cancerCetuximabPopulationPhases of clinical researchCancer researchRadiation therapyMedicineGastroenterology
222Publications
31H-index
3,984Citations
Publications 220
Newest
#1Salvatore AlfieriH-Index: 17
Last. Lisa Licitra (University of Milan)H-Index: 70
view all 29 authors...
To identify and validate baseline magnetic resonance imaging (b-MRI) radiomic features (RFs) as predictors of disease outcomes in effectively cured head and neck squamous cell carcinoma (HNSCC) pat...
Source
#1Stefano Cavalieri (University of Milan)H-Index: 11
#2Elena Colombo (University of Milan)H-Index: 14
Last. Lisa Licitra (University of Milan)H-Index: 70
view all 15 authors...
OBJECTIVE: To capture and monitor flu-like symptoms in relation to the clinical characteristics and the oncologic treatment of a large head and neck cancer (HNC) patient cohort during the Coronavirus disease 2019 (COVID-19) pandemic. METHODS: Patients were monitored through by 2 rounds of interviews. Clinical characteristics of patients with no symptoms (group 0) and of those reporting ⩾1 (group A), ⩾3 (group B), or ⩾5 symptoms (group C) were analyzed. Patients with ⩾1 symptom at both in...
Source
#1Francesca Platini (University of Milan)H-Index: 5
#2Stefano Cavalieri (University of Milan)H-Index: 11
Last. Laura D. Locati (University of Milan)H-Index: 31
view all 12 authors...
PURPOSE Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. METHODS From January 2015 to June 2019 we retrospectively reviewed clinical records of patients with RAI-resistant DTC treated with lenvatinib at Istituto Nazionale dei Tumori (Milan, Italy). New side effect of any grade, appeared after 12 months of lenvatinib, was d...
Source
PURPOSE To describe the management and outcomes of loco-regionally advanced (stages III-IV) laryngeal cancer (LRALC) in elderly patients. METHODS Clinical records of 88 LRALC patients treated at our Institution from 2002 to 2017 were retrospectively reviewed. Patients were divided in 2 subgroups: age > 65 years (elderly) and age ≤ 65 years (controls). Survivals were estimated with Kaplan-Meier method and compared with log-rank test, multivariate analysis were performed with Cox proportional haza...
Source
#1Carlotta Giani (UniPi: University of Pisa)H-Index: 9
#2Laura ValerioH-Index: 10
Last. Rossella Elisei (UniPi: University of Pisa)H-Index: 84
view all 17 authors...
Background: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. However, there are a lot of drug-related adverse events (...
5 CitationsSource
#1R. BerardiH-Index: 1
#2Mariangela Torniai (Marche Polytechnic University)H-Index: 15
Last. Erika Martinelli (Seconda Università degli Studi di Napoli)H-Index: 40
view all 12 authors...
ABSTRACT Introduction Coronavirus disease 2019 (COVID-19) has rapidly spread to every country around the world taking on pandemic proportions Since March 8th, 2020, the Italian government ordered a nationwide lockdown with unavoidable social isolation Healthcare professionals (HCPs) represent the most physically and emotionally involved category The aim of this study is to assess the social distress among HCPs in Italy Methods In this online, totally anonymous survey, 24 multiple choice question...
1 CitationsSource
Clinical data of ri-SGCs patients treated between 2015 and 2019 at a tertiary cancer center and a national hadron therapy facility were reviewed. Latent time (LT) from first RT to ri-SGCs diagnosis, overall (OS), and disease-free survival (DFS) were assessed. Thirteen patients developed 14 ri-SGCs (one patient had 2 synchronous ri-SCGs), after a median LT of 23 years (range 16–34). Parotid was the primary site in 8 cases (57%) and salivary duct carcinoma was the most frequent histotype (29%). Ni...
Source
PURPOSE Surgical complications such as hypoparathyroidism (HPT) or vocal cord palsy are seldom assessed when the quality of life (QOL) in thyroid cancer patients is investigated. The aim of this study was to measure the QOL difference in thyroid cancer survivors with and without HPT. METHODS Participants for this analysis were enrolled in 13 countries from a study that pilot-tested a thyroid cancer-specific QOL instrument. They were included if they had been diagnosed with thyroid cancer at leas...
1 CitationsSource
#1Anna CavalloH-Index: 7
#2Tiziana RancatiH-Index: 27
Last. E. OrlandiH-Index: 3
view all 18 authors...
Source
#2G. InfanteH-Index: 1
Last. E. OrlandiH-Index: 3
view all 15 authors...
Source